Apollomics Inc..
APLM.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Apollomics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of immuno-oncology and targeted therapies to treat cancer. The company develops a pipeline of drug candidates, including novel and combination therapies. Apollomics primarily focuses on addres...Show More
Better Health for All
-30
Apollomics Inc. is a biopharmaceutical company entirely focused on the discovery and development of oncology therapies, including vebreltinib (APL-101) for non-small cell lung cancer and other advanced tumors, and combination therapies for hepatocellular carcinoma and renal cell carcinoma.
1
Vebreltinib has received conditional approval in China for multiple indications and FDA Orphan Drug Designation for NSCLC with MET Genomic Tumor Aberrations.
2
The company's core business is dedicated to addressing unmet needs in cancer treatment and improving clinical benefits for patients globally, with no evidence of revenue from products with negative health outcomes. The company's lead program is in a Phase 2 multicohort clinical trial in the United States and over 10 other countries.
3
Clinical trials, such as APOLLO-1, have received ethics approval from committees compliant with national guidelines, and trials are based on sound mechanistic and scientific rationale.
4
Apollomics retains worldwide rights to Vebreltinib outside of mainland China, Hong Kong, and Macau, indicating limited patent flexibility.
5
The company supports the GO2 Foundation for Lung Cancer and programs offering resources for the oncology community, but no specific funding percentages are provided.
6
The company's R&D team generates novel molecules and strategically developed a global intellectual property portfolio, but no specific R&D budget allocation for health improvement is provided.
7
Fair Money & Economic Opportunity
0
Apollomics Inc. is a clinical-stage biotechnology company focused on developing oncology treatments.
1
The provided articles detail its pipeline, clinical trials, funding, and staff. The ethical value 'Fair Money & Economic Opportunity' is defined for activities that lend, insure, move, or store money, and its KPIs relate to financial products, services, and customer financial outcomes. As Apollomics Inc. operates in the biopharmaceutical sector and the articles contain no evidence of the company engaging in financial services or offering financial products to consumers, none of the KPIs under this value are applicable or have supporting evidence. Therefore, all KPIs are omitted.
Fair Pay & Worker Respect
-50
Apollomics Inc. terminated all U.S. staff, including its CEO and CFO, effective August 29, 2025.
1
The company has also called an extraordinary general meeting of shareholders for September 4, 2025, to vote on winding up the company.
2
No data is available for living wage coverage, CEO median pay ratio, collective bargaining share, safety incident rate, pay equity ratio, worker engagement score, labor violation incidents, insecure contract share, or health insurance coverage.
3
Fair Trade & Ethical Sourcing
0
No information was found regarding fair trade certifications, supplier audit frequency, forced or child labor incidents, supply chain traceability, remediation speed for violations, ethical clause coverage in contracts, materials risk index, or supplier diversity spend.
1
Honest & Fair Business
0
No evidence available to assess Apollomics Inc. on Honest & Fair Business.
Kind to Animals
-40
Apollomics Inc. conducts pre-clinical tests on animals to evaluate product safety profiles.
1
The company confirms in corporate disclosures that it utilizes animal subjects for product testing.
2
Specifically, its drug candidate Vebreltinib (APL-101) was tested for efficacy using preclinical studies that involved xenograft animal models and patient-derived xenograft models (PDX).
3
The company's policy allows for routine animal testing without evidence of specific restrictions or reduction goals.
4
No War, No Weapons
0
The provided articles for Apollomics Inc. (APLM.US) do not contain any information relevant to the 'No War, No Weapons' ethical value. The company is described as a biopharmaceutical firm focused on oncology.
1
The articles discuss Nasdaq compliance and the company's research and development in cancer treatment, but provide no data on arms contracts, dual-use technologies, sales to embargoed regimes, peacebuilding investments, or any other related metrics.
2
pertains to a different entity, Apollo Global Management, and is therefore not applicable to Apollomics Inc.
Planet-Friendly Business
0
The provided article focuses solely on Apollomics Inc.'s mission, vision, and pipeline of cancer treatments.
1
It does not contain any specific, factual data, actions, or policies related to environmental performance, climate action, or any other metrics relevant to the 'Planet-Friendly Business' ethical value.
2
Consequently, no assessment can be made against the specified KPIs due to a complete lack of evidence.
Respect for Cultures & Communities
0
No specific, concrete data points were found in the provided articles regarding Apollomics Inc.'s performance on any of the KPIs related to Respect for Cultures & Communities. The articles reviewed either focused on general company information, clinical trial regulations, or explicitly stated a lack of relevant data for the requested metrics.
Safe & Smart Tech
0
No evidence available to assess Apollomics Inc. on Safe & Smart Tech.
Zero Waste & Sustainable Products
0
No evidence available to assess Apollomics Inc. on Zero Waste & Sustainable Products.